Taken together, our in vitro and in vivo results comparing clinically relevant molecules provide a roadmap for the rapid screening of potent and selective liver targeting THRβ agonists for the potential treatment of NAFLD and NASH. Here, THRB is linked to metabolic dysfunction-associated steatotic liver disease.